Physician profile
Yuri Volk
NPI 1265562862
$5,453.15
in general payments reported to CMS, 2019-2025
25 companies · $1,289 in 2025
The $1,289 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $369 · 2021: $807 · 2022: $727 · 2023: $916 · 2024: $908 · 2025: $1,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,017 · Education: $56.35 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,017.33 |
| Education | $56.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,192.37 | 2019-2025 | Linzess, Viberzi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $722.75 | 2019-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $530.75 | 2022-2025 | Stelara, Tremfya, Simponi |
| Ardelyx, INC. | $393.14 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $349.51 | 2019-2025 | |
| Celgene Corporation | $313.26 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $236.64 | 2024-2025 | Voquezna |
| Vivus LLC | $178.26 | 2021-2025 | Qsymia, Pancreaze |
| Ironwood Pharmaceuticals, INC | $177.96 | 2019-2025 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $175.27 | 2019-2024 | Entyvio |
| Qol Medical, LLC | $162.74 | 2023-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $161.35 | 2020-2023 | |
| Madrigal Pharmaceuticals | $136.79 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $132.64 | 2020-2024 | Talicia |
| Allergan, INC. | $124.41 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $105.70 | 2024-2025 | Zenpep |
| Pfizer INC. | $89.41 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $84.54 | 2019-2025 | |
| Braintree Laboratories, INC. | $61.49 | 2021-2022 | |
| Genzyme Corporation | $27.71 | 2025 | |
| Concordia Pharmaceuticals INC. | $25.06 | 2019 | |
| W. L. Gore & Associates, INC. | $24.10 | 2023 | Gore Cardioform Septal Occluder |
| Celltrion USA INC. | $17.87 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $17.43 | 2025 | Iqirvo |
| Evoke Pharma, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuri Volk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.